Ron,
your interesting but your hypothesis has a hole in it.

microplasmas can bring viral infection into the brain - free radicals are then able to enter the cells, and create- dis -ease.

our brains are not leaking, but our medicine does break the BBB
in the form of dopamine, so it does work as a drug, but there may be other drugs that we are prescribed that cause it to be depleted faster.
or protein and our med's dont work because we eat proteins and take meds too close together -thus the dopamine also works as an amino acid and digests our food instead of helping us walk -stop shaking etc.
My hypothesis is that many are diagnosed incorrectly...

also - Starfield JAMA article: Barbara Starfield's JAMA article (Volume 284, No. 4, 2000), gives very large estimates of death due to medical treatment. A total of 225,000 deaths are attributed to various iatrogenic causes. This figure puts them at the 3rd highest cause of death, only after heart disease and cancer. With roughly 2.4 million US deaths in 1999, these estimates would put iatrogenic causes at approximately 9.3% of deaths.

see links there are many -here's one
http://www.wrongdiagnosis.com/mistakes/common.htm
or
http://www.wrongdiagnosis.com/news/y..._diagnosed.htm


you said

"How about this for a theory.
We all know dopamine can't pass the BBB, so in our medication, we take levodopa which can penetrate the BBB, and is converted to dopamine in the brain."
In the brain,

Drug Class And Mechanism:

Levodopa-carbidopa is a combination of two drugs, levodopa and carbidopa. Levodopa-carbidopa is used in the treatment of Parkinson's disease. Parkinson's disease is believed to be related to low levels of dopamine in certain parts of the brain. When levodopa is taken orally, it crosses through the "blood-brain barrier." Once it crosses, it is converted to dopamine. The resulting increase in brain dopamine concentrations is believed to improve nerve conduction and assist the movement disorders in Parkinson disease. Carbidopa does not cross the blood-brain barrier. Carbidopa is added to the levodopa to prevent the breakdown of levodopa before it crosses into the brain. The addition of carbidopa allows lower doses of levodopa to be used. This reduces the risk of side effects from levodopa such as nausea and vomiting. This combination medicine was approved by the FDA in 1988.

Prescription:Brand Name
Sinemet

Dosing: Levodopa-carbidopa is taken several times per day. It may be administered with food to reduce the likelihood of nausea. However, a high-protein diet may reduce its absorption.

Drug Interactions: The use of amantadine (Symmetrel), benztropine (Cogentin), procyclidine (Kemadrin), or trihexyphenidyl (Artane) with levodopa-carbidopa can enhance the anti-Parkinson's effects of levodopa. Droperidol, haloperidol (Haldol), loxapine (Loxitane), metoclopramide (Reglan), phenothiazines such as prochlorperazine (Thorazine); thioxanthenes as thiothixene (Navane) inhibit dopamine in the brain. These drugs, therefore, can worsen Parkinson's disease and reverse the beneficial effects of levodopa. Methyldopa (Aldomet) and reserpine also can interfere with the beneficial actions of levodopa-carbidopa and can increase the risk of side effects.

Phenytoin (Dilantin) can increases the break-down of levodopa-carbidopa, reducing its effectiveness.

Use of levodopa-carbidopa with monoamine oxidase inhibitors (MAOI's) antidepressants, for example, isocarboxazid (Marplan), phenelzine (Nardil), tranylcypromine (Parnate), and procarbazine (Matulane), can result in severe and dangerous elevations in blood pressure. MAOI's should be stopped 2-4 weeks before starting levodopa-carbidopa therapy.

Related Links on MedicineNet.com